Abstract
Steroïdresponsieve meningitis-arteritis (SRMA) is een vaak voorkomende neurologische aandoening bij jonge honden. Typische klinische symptomen voor de acute vorm van SRMA zijn nekpijn, depressie en koorts. Deze casereport beschrijft een 1,5 jaar oude pointer met zeldzame neurologische symptomen (unilaterale uitval van verschillende craniale zenuwen en Horners syndroom) en een uitzonderlijke necrose van de tong. Het tongletsel was vermoedelijk onderdeel van de systemische vasculitis ten gevolge van SRMA. De behandeling werd verder gecompliceerd door het ontstaan van een staarttopnecrose en iatrogene calcinosis cutis.
Highlights
Steroid responsive meningitis-arteritis (SRMA) is a frequently recognized neurological disorder in dogs
Immunoglobulin A (IgA) levels in serum and cerebrospinal fluid (CSF) were severely elevated (366 μg/ml, reference range< 100 μg/ml and >3 μg/ml, reference range < 0.2 μg/ml respectively). This supported the diagnosis of steroid responsive meningitis-arteritis (SRMA) and the dog was discharged on prednisolone (Prednisolone®, Kela Laboratoria) at a dosage of 0.5 mg/kg per os (PO) q 12 hr
A young dog was presented with some atypical features of acute SRMA
Summary
Steroid responsive meningitis-arteritis (SRMA) is a frequently recognized neurological disorder in dogs. Because of persisting fever despite antibiotics, a diagnosis of steroid responsive meningitis-arteritis (SRMA) was considered possible and prednisolone (Prednisolone®, Kela Laboratoria) was added at a dosage of 0.5 mg/kg subcutaneously (SC) q 24 hr This resulted in some improvement of the clinical symptoms, but the fever waxed and waned and the antibiotic therapy was changed to cefotaxim (Claforan®, Sanofi-Aventis) (20 mg/kg IV q 6 hr). Immunoglobulin A (IgA) levels in serum and CSF were severely elevated (366 μg/ml, reference range< 100 μg/ml and >3 μg/ml, reference range < 0.2 μg/ml respectively) This supported the diagnosis of SRMA and the dog was discharged on prednisolone (Prednisolone®, Kela Laboratoria) at a dosage of 0.5 mg/kg per os (PO) q 12 hr. On follow-up 1.5 years later, none of the complaints had recurred
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
